This unique 7.2% dividend yield triple-net healthcare REIT comes with its own unique risks and advantages. Its dividend is well covered and has been increased for 17 consecutive years, and the company fared better than other healthcare REITs during the pandemic. In this article, we review the business model, dividend safety, valuation and risks. We conclude with our opinion on investing.
A Note on Recent Market Volatility
The market has been volatile this year, and it’s left a lot of investors feeling very uncomfortable. Contributing factors have ranged from a surge in oil prices, to upward moves in interest rates, the unwinding of many “pandemic trades,” bitcoin narratives, market fear mongers, and of course the ever present chorus of nonsensical get-rich-quick people. We have some very strong advice for anyone feeling unsettled about the market. If you’ve been following Blue Harbinger long enough then you’ve likely heard it many times before. It’s worth repeating now…
Attractive Real Estate CEF: 7.2% Yield, Paid Monthly, Discounted Price
If you are looking for a compelling, out-of-the-box way to play the strengthening real estate sector, this closed-end fund (“CEF”) is worth considering. It offers a healthy 7.2% yield (paid monthly), it trades at a discounted price (versus its NAV), and it has a growing track record of success. Plus the real estate sector is currently attractive (we’ll explain). In this report, we review the fund strategy, holdings, leverage, expense ratio, pricing/valuation, and why we believe the opportunity is particularly compelling if you are a long-term income-focused investor.
This Media Platform Stock: Rapid Rise to Resume
This on-device media platform is attractive because of its business model, rapid growth (~115% in FY21), expanding margins, solid free cash flow generation and large market opportunity. Further, the recent share price sell off (it’s still below its all-time highs due to the the recent mini “tech wreck”) has created an attractive entry point for long-term investors. In this report, we review the health of the business, valuation, risks, and then conclude with our opinion on investing.
Main Street Capital: 6.3% Yield, Pandemic Challenges
Main Street Capital (MAIN) is a popular BDC (business development company) thanks to its big monthly dividend payments (which have never been reduced in the history of the company). Main Street provides financing solutions to a wide variety of smaller businesses—many of which were incidentally hit particularly hard by covid. The shares have not yet recovered to their pre-covid level, and in this report we review the business, the financials, the dividend, the risks and finally conclude with our opinion on investing.
Life Sciences Cloud Software Company: Even More Attractive on the Recent Price Pullback
There is a large and growing demand for cloud-based software in the life sciences industry, and the company we review in this report is the clear market leader (with a lot of long-term upside). And despite a recent earnings beat and guidance raise (on top of its already rapidly growing business) the shares have recently sold off (as part of the broader market’s recent sell off of top growth stocks in general). We believe these factors have combined to create an attractive buying opportunity, and we share all the details in this report, including a review of the business, growth prospects, valuation and risks. If you are a long-term investor, these shares are worth considering for a spot in your portfolio.
New Options Trade: Chip Selloff Creates High Income Opportunity
Buying great businesses when they’re out of favor can work well over the long-term. This report reviews a compelling income-generating options trade on a very attractive semiconductor business that is currently/temporarily out of favor. Specifically, the share price is down as supply chain uncertainties add to sector momentum challenges. These factors have combined to create an attractive options trade opportunity that puts compelling upfront premium income in your pocket, and gives you a chance to pick up these attractive shares at an even lower price. We believe the trade is attractive to place today, and potentially over the next few trading sessions, as long as the share price doesn’t move too dramatically before then.
Attractive Growth, Share Price Pullback
If you are looking for a steady dividend-growth stock, this report is not for you. However, if you are looking to add a little powerful long-term price appreciation to your portfolio, these shares are worth considering, especially on the recent price pullback. The company is well-positioned as a premium brand in China, it enjoys rapid sales growth and a large and growing total addressable market, and it has the backing of the Chinese government. In this report, we review the company’s business model, market opportunity, COVID-19 impacts, competitive position, valuation and risks. We conclude with our opinion on whether the company offers an attractive risk-reward versus its long-term growth opportunity.
Performance Update: More Gains & The Pandemic Trade’s Future
The Blue Harbinger “Disciplined Growth” portfolio and the “Income Equity” portfolio both posted positive gains (again) in February (thereby extending their growing long-term track records of top performance). However, if you haven’t noticed, the market has been particularly volatile for top growth stocks over the last few weeks. More specifically, the “pandemic trade” is crashing. In this report, we share the latest performance of our top idea portfolios, and offer some tried and true advice (and specific ideas) about current market conditions going forward.
Attractively Priced Natural Gas Play (Steady Growing Dividend)
If you are looking to add an extraordinarily steady growing dividend to your portfolio, this diversified natural gas company is worth considering. It has increased its dividend payment for 50 consecutive years (it currently yields 3.9%) and it offers the potential for healthy price appreciation. In this article, we dig deeper into the company’s dividend and growth prospects by reviewing the health of the business, cash flows, balance sheet strength, valuation and risks. We conclude with our opinion on why it’s worth considering if you are a long-term income-focused investor.
New Options Trade: Very High Upfront Income, Value-Based Healthcare
This recently public company (August 2020) is on a tremendous growth trajectory (very high growth rate) as it delivers its highly differentiated, technology-enabled, value-based care model for Medicare. The shares are worth considering for purchasing outright, however this report highlights a particularly attractive income-generating options trade. Specifically, the trade puts compelling upfront income in your pocket (that you get to keep no matter what) and it gives you a shot at picking up the shares at an even lower price. We believe this is an attractive trade to place today (and potentially over the next few trading sessions) as long as the price doesn’t move too dramatically ahead of the company’s earnings announcement expected on March 8th.